Patients with unresectable hepatocellular carcinoma (HCC) face limited survival benefits from transarterial chemoembolization (TACE) alone. New data from the CHANCE2005/CARES-005 trial indicate that combining TACE with camrelizumab and rivoceranib significantly improves overall survival in this population.1
Unresectable hepatocellular carcinoma (HCC) presents a significant clinical challenge, with transarterial chemoembolization (TACE) serving as a standard treatment. However, the efficacy of TACE alone in improving long-term survival for these patients has been limited.1 The need for more effective systemic approaches, particularly those integrating immunotherapy and targeted therapy, has been a focus of ongoing research.1
The CHANCE2005/CARES-005 Trial
The CHANCE2005/CARES-005 study was a randomized phase II trial designed to evaluate the addition of camrelizumab (an anti-PD-1 antibody) and rivoceranib (a vascular endothelial growth factor receptor 2 inhibitor) to TACE for patients with unresectable HCC.1 The trial compared two arms: TACE combined with camrelizumab and rivoceranib versus TACE alone.1
The study aimed to determine if this combination therapy could offer a survival advantage over TACE monotherapy.1 While the abstract does not specify the exact number of patients enrolled or the primary endpoint, it highlights the comparative nature of the trial in assessing the efficacy of the combination regimen.1
Key Findings
The trial demonstrated that TACE combined with camrelizumab and rivoceranib improved overall survival (OS) compared to TACE alone in patients with unresectable HCC.1 Specific hazard ratios or p-values for OS were not provided in the abstract, but the statement indicates a positive outcome for the combination arm.1 This suggests that the synergistic effects of immune checkpoint inhibition and anti-angiogenic therapy, when combined with locoregional TACE, may overcome some of the limitations of TACE monotherapy.1
Another study, PMID 41107646, focused on the underutilization of staging laparoscopy prior to neoadjuvant systemic therapy in gastric cancer.2 While this paper addresses a critical aspect of gastric cancer management, its findings are not directly related to the treatment approaches for unresectable HCC or the specific combination therapy evaluated in the CHANCE2005/CARES-005 trial.2 The abstract for PMID 41107646 incorrectly describes the content of PMID 41734362, indicating a potential error in the provided research abstract.2 Therefore, the information regarding gastric cancer staging laparoscopy is noted but not integrated into the discussion of HCC treatment efficacy.2
Limitations and Next Steps
As a phase II trial, CHANCE2005/CARES-005 provides preliminary evidence of efficacy.1 The abstract does not detail safety profiles, specific adverse events, or quality of life outcomes, which are crucial for a comprehensive understanding of the treatment's clinical utility.1 Further phase III trials with larger patient cohorts are necessary to confirm these survival benefits, establish the long-term safety profile, and define the optimal patient population for this combination therapy.1 The absence of detailed statistical measures (e.g., HR, p-value) in the abstract limits a precise quantitative assessment of the observed improvement.1
The CHANCE2005/CARES-005 trial offers a glimpse into a potentially more effective treatment strategy for unresectable hepatocellular carcinoma. For clinicians managing these complex cases, the prospect of combining TACE with an anti-PD-1 antibody like camrelizumab and an anti-VEGFR2 inhibitor such as rivoceranib suggests a new avenue beyond current standards. While the phase II nature and limited data in the abstract necessitate caution, the reported improvement in overall survival is a signal that warrants attention. It underscores the ongoing shift towards multi-modal approaches, integrating systemic therapies with locoregional treatments.
From an industry perspective, this trial highlights the continued investment in combination therapies, particularly those involving immune checkpoint inhibitors and targeted agents. Companies like Hengrui Pharma, which develops camrelizumab, and Elevar Therapeutics, associated with rivoceranib, will likely pursue further development and larger trials to solidify these findings. The market for HCC treatments remains competitive, and demonstrating a clear survival advantage, even in a phase II setting, can influence future research directions and potentially impact guideline recommendations if confirmed in subsequent studies.
For patients, these results offer a degree of optimism. Unresectable HCC carries a poor prognosis, and any therapy that can extend overall survival is significant. While it is premature to alter clinical practice based solely on a phase II abstract, the data suggest that patients may eventually have access to more effective treatment options, potentially improving their quality of life and longevity. The integration of these agents into standard care would represent a meaningful step forward, moving beyond the current limitations of TACE monotherapy.
- The Pivot TACE alone has limited efficacy in unresectable HCC.
- The Data TACE combined with camrelizumab and rivoceranib improved overall survival compared to TACE alone.1
- The Action Consider combination therapy for unresectable HCC, pending further phase III data.
ART-2026-154
Cite This Article
Team TLSFE. Tace + camrelizumab/rivoceranib improves os in unresectable hcc. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/oncology/solid-tumors/news/tace-camrelizumab-rivoceranib-unresectable-hcc.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Zhu HD, Fan WJ, Zhao C. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026.
2. Ostowari A, Chen KT, Hasjim BJ. Underutilization of Staging Laparoscopy Prior to Neoadjuvant Systemic Therapy in Gastric Cancer. Ann Surg Oncol. 2026.
